Previous 10 | Next 10 |
2024-02-23 10:00:17 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming UBS concedes it wasn't bullis...
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2 Clinical Trial – MELBOURNE, Australia and SAN FR...
- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today an...
– Preliminary Data from ATH434-202 Study Expected in 1H 2024 – – ATH434-201 Study to Complete in November 2024 – MELBOURNE, Australia and SAN FRANCISCO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity&...
2023-12-21 01:05:44 ET More on Alterity Therapeutics: Alterity jumps after promising data on Parkinson's candidate Seeking Alpha’s Quant Rating on Alterity Therapeutics Historical earnings data for Alterity Therapeutics For further details see: Alt...
MELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today an...
2023-12-06 08:38:42 ET More on pre-market losers and stocks. NeuroSense: A Hold Ahead Of Phase 2b ALS Data NeuroSense ALS candidate meets key study goals Janover inks strategic referral partnership with La Rosa Holdings Seeking Alpha’s Quant Rating on ...
2023-12-05 08:28:55 ET Losers: Replimune Group ( REPL ) -50% presents new data from IGNYTE clinical trial of RP1 in Anti-PD1 failed Melanoma and non-Melanoma skin cancers. iBio ( IBIO ) -38% announces pricing of $4.5 Million public offering . Designer B...
MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be ...
News, Short Squeeze, Breakout and More Instantly...
Alterity Therapeutics Limited Company Name:
ATHE Stock Symbol:
NYSE Market:
MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Com...
MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today an...
- New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt Universi...